Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2002

View Archived Issues

Coumarin-based compounds as leads for new antiviral agents for measles

Hemolink deemed not approvable by Canadian authorities

Atrix initiates phase II trial of low-dose oral interferon alfa product in oral warts

Isotechnika enters negotiations for drug development agreement

Encouraging phase I results reported for StreptAvax vaccine

Pegasys recommended for approval in E.U. for chronic hepatitis C

Vernalis presents annual progress review

Minimally invasive treatment for GERD safe and effective in long-term human trial

Potent, selective, orally active vasopressin V1b receptor antagonist characterized

Speedel enters agreement with Roche for new class of renin inhibitors

Angiogenic growth factor therapy evaluated for CAD in FIRST trial

Label change for Xenical cleared by CPMP

Efficacy, pharmacokinetic and exposure-response data discussed in Baltimore for pregabalin

Galanin: role in Alzheimer's disease

Remicade granted priority review as Crohn's disease monotherapy

Transition Therapeutics confirms efficacy of interferon combination therapy

Vfend receives marketing approval in Europe for the treatment of fungal infections

Seattle Genetics initiates phase I monoclonal antibody study

Antagonists of human 11CBy receptor claimed for diabetes, depression, etc.

Novel anticoagulants designed at 3-D

Sanofi-Synthelabo reports preparation and use of new benzimidazoles

New PDE5 inhibitors from Almirall Prodesfarma and their use

Recent patent covers Agouron's CDK inhibitors

Inhibitors of fatty acid synthase FabH under study at GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...